Anteris Technologies ( (AU:AVR) ) has issued an update.
Anteris Technologies announced the partial exercise of the over-allotment option related to its initial public offering in the U.S., involving 78,481 shares of common stock at $6.00 per share. The stabilisation period for its stock, managed by TD Cowen, concluded on January 12, 2025, after market stabilisation activities included the purchase of 2,141,519 shares at prices between $5.14 and $6.00. This development marks a significant step in the company’s market presence and operational expansion in the U.S. market.
More about Anteris Technologies
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing advanced medical devices aimed at restoring healthy heart function. Founded in Australia, the company has a strong presence in Minneapolis, USA, a prominent MedTech hub. Anteris’ flagship product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis using its patented ADAPT tissue technology, which has been utilized in over 55,000 patients worldwide.
Average Trading Volume: 3,501
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $175.7M
See more insights into AVR stock on TipRanks’ Stock Analysis page.